or
forgot password
  • cancer clinical trials in boston, MA

  • Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
    Massachusetts General Hospital

    Trial Locations
    Massachusetts General Hospital
    Beth Israel Deaconess Medical Center`
    Renal Cell Carcinoma, Neoplasm Metastases
    Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Brain and Central Nervous System Tumors, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Precancerous Condition
    CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
    Dana Farber Cancer Institute
    Boston, Massachusetts 02115
    Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
    Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
    Boston University Cancer Research Center
    Boston, Massachusetts 02118
    Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
    Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hosptial
    Non-small Cell Lung Cancer
    Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber/Brigham and Women's Cancer Center
    Boston University Cancer Research Center
    Prostate Cancer
    Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Boston Medical Center
    Brigham and Women's Hospital
    Neuroendocrine Carcinoma
    Simvastatin in Waldenstrom's Macroglobulinemia
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Waldenstrom's Macroglobulinemia
    Irinotecan and ABT-888 in Treating Patients With Metastatic or Unresectable Cancer
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult Non-Hodgkin Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult Non-Hodgkin Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
    RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Pancreatic Neuroendocrine Tumor
    SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Mucosal Melanoma, Acral/Lentiginous Melanoma
    Preoperative Cisplatin and Bevacizumab in ER-, PR-, Her-2 Negative Breast Cancer
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Breast Cancer
    Smoking Cessation Intervention for Patients Undergoing Lung Surgery
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Lung Cancer
    Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    Pancreatic Cancer
    Efficacy and Safety of 500mg of Fulvestrant as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hosptial
    Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
    Boston Medical Center
    Boston, Massachusetts 02118
    Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Lymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity, Sarcoma
    Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
    Dana Farber Cancer Institute
    Boston, Massachusetts 02115
    CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
    Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Non-rhabdomyosarcoma Soft Tissue Sarcoma, Bone Sarcoma
    Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Nasopharyngeal Carcinoma
    Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Rhabdomyosarcoma
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Brigham and Women's Hospital
    Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
    Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    B-cell Chronic Lymphocytic Leukemia, Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
    Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber/Brigham and Women's Cancer Center
    Boston University Cancer Research Center
    Colorectal Cancer
    Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    Breast Cancer
    Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Boston, Massachusetts 02115
    Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
    Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Hepatic Veno-Occlusive Disease